Details of the Drug

General Information of Drug (ID: DMN5T2A)

Drug Name
Ciclopirox
Synonyms
Ciclopiroxum; Cyclopirox; Cyclopyroxolamine; Loprox; Penlac; Stieprox; Terit; Ciclopirox Olamin; Ciclopirox gel; Loprox Gel; Loprox Shampoo; Loprox cream; Penlac nail lacquer; HOE 296b; Batrafen (TN); Ciclopirox-Olamin; Ciclopiroxum [INN-Latin]; Dafnegin-CSC; HOE-296; HOE-296b; Loprox (TN); Penlac (TN); Stieprox (TN); Ciclopirox (USP/INN); Ciclopirox [USAN:BAN:INN]; (6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone); 6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridinone; 6-Cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone; 6-Cyclohexyl-1-hydroxy-4-methyl-2-(1H)-pyridone; 6-cyclohexyl-1-hydroxy-4-methyl-2(1 H)-pyridinone; 6-cyclohexyl-1-hydroxy-4-methylpyridin-2(1H)-one; 6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one
Indication
Disease Entry ICD 11 Status REF
Fungal infection 1F29-1F2F Approved [1]
Therapeutic Class
Antifungal Agents
Drug Type
Small molecular drug
Structure
3D MOL 2D MOL
#Ro5 Violations (Lipinski): 0 Molecular Weight (mw) 207.27
Topological Polar Surface Area (xlogp) 2
Rotatable Bond Count (rotbonds) 1
Hydrogen Bond Donor Count (hbonddonor) 1
Hydrogen Bond Acceptor Count (hbondacc) 2
ADMET Property
Half-life
The concentration or amount of drug in body reduced by one-half in 1.7 hours [2]
Metabolism
The drug is metabolized via the glucuronidation [3]
Chemical Identifiers
Formula
C12H17NO2
IUPAC Name
6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one
Canonical SMILES
CC1=CC(=O)N(C(=C1)C2CCCCC2)O
InChI
InChI=1S/C12H17NO2/c1-9-7-11(13(15)12(14)8-9)10-5-3-2-4-6-10/h7-8,10,15H,2-6H2,1H3
InChIKey
SCKYRAXSEDYPSA-UHFFFAOYSA-N
Cross-matching ID
PubChem CID
2749
ChEBI ID
CHEBI:453011
CAS Number
29342-05-0
DrugBank ID
DB01188
TTD ID
D07GRH
VARIDT ID
DR00986
ACDINA ID
D00945

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
HIF-prolyl hydroxylase (HPH) TTJQFBG NOUNIPROTAC Modulator [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease Fungal infection
ICD Disease Classification 1F29-1F2F
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
HIF-prolyl hydroxylase (HPH) DTT NO-GeName 7.70E-01 4.40E-03 0.02
Molecular Expression Atlas (MEA) Jump to Detail Molecular Expression Atlas of This Drug

Drug Inactive Ingredient(s) (DIG) and Formulation(s) of This Drug

DIG
DIG Name DIG ID PubChem CID Functional Classification
Benzyl alcohol E00010 244 Antimicrobial preservative; Solvent
Cetyl alcohol E00061 2682 Coating agent; Emollient; Emulsifying agent; Stiffening agent
Docusate sodium E00563 23673837 Surfactant
Ethyl acetate E00192 8857 Flavoring agent; Solvent
Isopropyl alcohol E00070 3776 Antimicrobial preservative; Solvent
Lactic acid E00020 612 Acidulant
Sodium chloride E00077 5234 Diluent; Tonicity agent
Sodium hydroxide E00234 14798 Alkalizing agent
Sodium laureth-3 sulfate E00564 23674622 Surfactant
Stearyl alcohol E00172 8221 Emollient; Emulsifying agent; Stiffening agent; Viscosity-controlling agent
Water E00035 962 Solvent
Laureth-2 E00376 76457 Dispersing agent; Emulsifying agent; Gelling agent; Penetration agent; Solubilizing agent; Surfactant; Viscosity-controlling agent
Myristyl alcohol E00171 8209 Emollient; Emulsion stabilizing agent; Oleaginous vehicle; Surfactant; Viscosity-controlling agent
Octyldodecanol E00269 21414 Emollient; Emulsifying agent; Lubricant; Solvent; Viscosity-controlling agent
Sorbitan monostearate E00524 16218600 Dispersing agent; Emulsifying agent; Solubilizing agent; Surfactant; Suspending agent; Vaccine adjuvant
Disodium laureth sulfosuccinate E00713 10173122 Surfactant
⏷ Show the Full List of 16 Pharmaceutical Excipients of This Drug
Pharmaceutical Formulation
Formulation Name Drug Dosage Dosage Form Route
Ciclopirox 0.77% cream 0.77% Cream Topical
Ciclopirox 0.77% suspension 0.77% Suspension Topical
Ciclopirox 0.77% gel 0.77% Gel Topical
Ciclopirox 8% solution 8% Solution Topical
Ciclopirox 1% shampoo 1% Shampoo Topical
Jump to Detail Pharmaceutical Formulation Page of This Drug

References

1 FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 076435.
2 Trend Analysis of a Database of Intravenous Pharmacokinetic Parameters in Humans for 1352 Drug Compounds
3 FDA approval: ado-trastuzumab emtansine for the treatment of patients with HER2-positive metastatic breast cancer. Clin Cancer Res. 2014 Sep 1;20(17):4436-41.
4 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
5 DOI: 10.1038/nrd4422
6 DOI: 10.1038/nrneph.2015.82
7 Discovery of Molidustat (BAY 85-3934): A Small-Molecule Oral HIF-Prolyl Hydroxylase (HIF-PH) Inhibitor for the Treatment of Renal Anemia. ChemMedChem. 2018 May 23;13(10):988-1003.
8 Inhibition of Prolyl Hydroxylases Increases Erythropoietin Production in ESRD
9 Company report (Daiichisankyo)
10 Pharmacological Characterization of ZYAN1, a Novel Prolyl Hydroxylase Inhibitor for the Treatment of Anemia. Drug Res (Stuttg). 2016 Feb;66(2):107-12.
11 Prolyl hydroxylase inhibition corrects functional iron deficiency and inflammation-induced anaemia in rats. Br J Pharmacol. 2015 Aug;172(16):4078-88.